Aims-To develop an in vitro assay for the putative glutamyl endopeptidase, "aggrecanase", which is thought to degrade cartilage aggrecan, and to examine the role of the enzyme in tumour necrosis factor stimulated aggrecan cleavage. Methods-Aggrecan fragments released by bovine nasal cartilage explants, with and without exposure to tumour necrosis factor a, were purified and analysed by western blotting and N-terminal sequencing. Intact bovine aggrecan was incubated with extracts of cartilage, lysed chondrocytes, or cartilage explant conditioned culture medium under a variety of conditions. Deglycosylated aggrecan was incubated with nasal cartilage explants. Proteoglycan breakdown was assessed by metachromatic assay of fragments in culture media, and cleavage of the substrate at the aggrecanase cleavage site was detected and measured using the antibody BC3, which recognises a neoepitope produced by aggrecanase cleavage of aggrecan.
Results-Aggrecan fragments generated from explants treated with tumour necrosis factor had N-terminal sequences consistent with cleavage of aggrecan at a restricted number of glutamyl bonds. Aggrecanase generated fragments were found in cartilage explant culture medium and chondrocyte monolayers. However, no aggrecanase activity could be detected in extracts of cartilage, or chondrocytes from which endogenous aggrecan fragments had been removed, under a variety of assay conditions. Deglycosylated aggrecan, added to explant cultures, efficiently inhibited endogenous aggrecan breakdown. Conclusions-Aggrecanase is active in cartilage and in chondrocyte monolayers, and its action is stimulated by tumour necrosis factor a. However, activity due to this enzyme could not be detected in vitro under our assay conditions, although a deglycosylated version of the substrate inhibited aggrecan breakdown in explant cultures. Aggrecan is lost from articular cartilage during the development of arthritis,2 compromising the correct functioning of the joint and possibly leading to damage to other components of cartilage, such as type II collagen.
Despite over 40 years of research, the mechanisms of aggrecan breakdown are only poorly understood. The process appears to be largely chondrocyte mediated,3 wherein the cell responds to catabolic stimuli, such as those produced in response to the proinflammatory cytokines, interleukin (IL)-1 , and tumour necrosis factor (TNF).5 Changes in chondrocyte gene expression lead to the manifestation of a catabolic phenotype driven by a putative proteolytic cascade6; evidence implicating certain proteolytic enzymes in this cascade has recently been reviewed.7 It has been shown, for instance, that inhibitors of matrix metalloproteinases,' 8-11 and of cathepsin B (E.C.3.4.22.1),6 can inhibit chondrocyte mediated aggrecan breakdown that has been stimulated by cytokines or retinoic acid.
Aggrecan fragments identified in the synovial fluid of normal bovine knee joints, osteoarthritic human knees,'2 injured joints, and the joints of patients with acute pyrophosphate arthritis, reactive arthritis, psoriatic arthritis, and juvenile rheumatoid arthritis'3 have the same N-terminal sequence. The corresponding aggrecan fragments have been isolated from the conditioned culture media of bovine cartilage explants maintained in the presence or absence of IL-1 and retinoic acid,6 14-16 and from retinoic acid stimulated chondrosarcoma cells.'7 These fragments appear to be formed by the action of an endopeptidase with specificity for cleavage between glutamic acid and a small aliphatic amino acid. Although the identity of this enzyme remains obscure, it has been referred to as "aggrecanase".'" Recent evidence suggests that aggrecanase may be a metalloproteinase, but not one of the known secreted matrix metalloproteinases. " Despite the knowledge that cartilage explants respond to exposure to TNF, as they do to IL-1,4' by increasing the rate of proteoglycan breakdown, the N-terminal sequences of aggrecan fragments released as a result of TNF treatment have not been examined. Hence, to date, there is no direct evidence for the involvement of aggrecanase in the TNF mediated catabolic response.
The N-terminal neoepitope produced by aggrecanase cleavage can be identified by use of the monoclonal antibody BC3.`9 We have used this antibody in an attempt to identify aggrecanase activity in lysates of cultured chondrocytes, cartilage explants, and explant conditioned culture medium, and have examined the N-terminal sequences of aggrecan fragments produced in response to TNF.
Methods
Reagents used for tissue culture were supplied by Life Technologies, Paisley, UK. Where reagents are not standard analytical grade their supplier is specified.
CARTILAGE EXPLANT CULTURES
Bovine nasal septum cartilage explants were prepared and cultured as described previously. 20 Mediators of proteoglycan degradation were added to these cultures as follows: all-transretinoic acid (Ret), (Sigma Chemical Company, Poole, Dorset, UK) to a final concentration of 1 iM from a freshly prepared stock solution in dimethyl sulphoxide (Me,SO); recombinant human IL-la (rhIL-la) specific activity 5 x 107 U/mg (from Dr K Roy, Glaxo, Greenford, UK) and specific activity 1.2 x 108 U/mg (from Dr S Dower, Immunex, Seattle, WA, USA) to a final concentration of 0.3 nM; or recombinant human TNFa (rhTNFa) specific activity 8 x 1 07 U/mg (from Dr E Amento, Genentech Inc, Boulder, CO, USA) to a final concentration of 3 nM. Explants with and without rhIL-la were cultured for two days, and with or without rhTNFa, or Ret, for five days, with a change of medium on day 2.
CHONDROCYTE CELL CULTURE
Cartilage from bovine nasal septum or metacarpophalangeal joints was obtained by dissection and all extraneous soft tissue was discarded. The cartilage was diced into pieces of approximately 2 mm3. These were washed in Dulbecco's phosphate buffered saline (DPBS) containing antibiotics (penicillin, 100 U/ml; streptomycin, 100 gg/ml; amphotericin B, 0.2 gg/ml). Each 4 M guanidinium chloride and proteinase inhibitors (1 mM phenylmethylsulphonyl fluoride, 10 ,M L-3-carboxy-2,3-trans-epoxypropionyl-leucylamido(4-guanidino) butane (E64), 0.1 mM 1,10-phenanthroline, and 1 gg/ml pepstatin). Proteoglycan was precipitated from the extraction mixture by addition of three volumes of ethanol, and recovered by centrifugation (245 xg, 4°C). The pellet was dissolved in 1 M potassium acetate, pH 7.0, containing proteinase inhibitors, reprecipitated with ethanol, and resuspended in a minimal volume ofwater overnight at 4°C. The ethanol precipitation was repeated, the pellet washed with water, and then freeze-dried. AGGRECAN 
FRAGMENTS
Cartilage explant culture media containing fragments of aggrecan were freeze-dried. PROTEOGLYCAN 
DEGLYCOSYLATION
The freeze-dried samples, either intact proteoglycan or culture medium containing proteoglycan fragments, were resuspended in a minimal volume of deglycosylation buffer (0.1 M Tris/0. 1 M sodium acetate, adjusted to pH 7.0 with HCI) and incubated with proteinase-free chondroitin ABC lyase (EC 4.2.2.4) and keratan-sulphate endo-1 ,4-beta-galactosidase (keratanase, endo-betagalactosidase, EC 3.2.1.103) (ICN Flow, Thame, Oxfordshire, UK) (1 mU/ig sulphated glycosaminoglycan (sGAG) estimated by a dye-binding assay)" at 37°C until no further sGAG removal was detected. The deglycosylated material was washed with three volumes of ethanol, three volumes of 80% (vol/vol) ethanol, air-dried, and frozen.
ADDITION OF DEGLYCOSYLATED PROTEOGLYCAN TO EXPLANT CULTURES
Deglycosylated proteoglycan (prepared as above) was suspended in DMEM, and the protein concentration was estimated by the BioRad dye-binding assay. The material was added at concentrations ranging from 0-1.41 mg/ml (-3.5 jiM assuming an average molecular mass of 400 000 for the deglycosylated proteoglycan) to bovine nasal septum cartilage explants cultured with and without rhIL-la. The cultures were incubated for two days, after which released endogenous proteoglycan was assayed with dimethylmethylene blue," and fragmentation of the exogenous deglycosylated proteoglycan was assessed by western blotting.
IMMUNOBLOTTING
Samples to be analysed by western blots were separated by 4-10% gradient polyacrylamide gel electrophoresis (PAGE) in the presence of sodium dodecyl sulphate (SDS),'3 or by "Aggrecanase" activity in tumour necrosis factor a mediated cartilage aggrecan breakdown SDS-PAGE.'4 Prior to loading, sGAG chains were removed by deglycosylation. Following electrophoresis proteins were transferred on to polyvinylidene difluoride (PVDF) membranes (Millipore, Watford, Hertfordshire, UK) by electroblotting in 10 mM 3-(cyclohexylamino)-l-propanesulphonic acid, 10% methanol, pH 11.0, for one and a half hours at 250 mA. The membranes were treated with 20 mM sodium/potassium phosphate, 0.15 M NaCl, pH 7.2, containing 5% (vol/vol) horse serum (blocking buffer) for at least four hours. Filters were then incubated with primary antibody, either BC3 (1:1000 dilution) which detects the N-terminal neoepitope generated by aggrecanase action on the aggrecan interglobular domain,"9 or 3B3 (1:256 dilution) which detects disaccharide stubs on deglycosylated aggrecan (ICN Flow),'5 for one hour at ambient temperature before washing (5 x 30 seconds) in blocking buffer. Filters were incubated with the second antibody (goat antimouse immunoglobulin, conjugated with alkaline phosphatase; Promega, Southampton, UK) at 1:500 dilution for one hour, and washed as above. Finally, the blots were developed using the AP colour detection kit (Bio-Rad, Hemel Hempstead, Hertfordshire, UK).
Samples (1 gl) for quantitative analysis by dot blot immunoassay were spotted on to dry nitrocellulose filters (Bio-Rad). The filters were incubated for 30 minutes in a humid atmosphere before the blots were processed for BC3 and 3B3 reactivity as described above.
PREPARATION OF CHONDROCYTE AND CARTILAGE EXTRACTS
Chondrocytes were cultured for at least one week before the cell layer was obtained using a cell scraper. The cells were then taken up in approximately one volume of either 50 mM Tris/HCl, pH 7.5, or 16 mM 2-(Nmorpholino)ethane sulphonic acid (Mes), pH 5.5, containing 0.1% or 3% Triton-X100 (lysis buffers), and freeze-thawed twice. Cell debris was removed by centrifugation at 10 000 xg for 10 minutes, and the supernatant was used in the in vitro aggrecanase assay.
Cartilage discs were crushed at -70°C by hitting the frozen tissue, contained in a cooled chamber, with a piston and mallet. 
CaCl2, pH 7.5, or 16 mM Mes, pH 5.5, before they were assayed for aggrecanase activity.
Aggrecanase assays were carried out in either 16 mM Tris/HCl buffer, 4 mM CaCl2, pH 7.5
(to detect the activity of putative serine or metalloproteinases), or 16 mM Mes, pH 5.5, with or without 5 mM cysteine (for the detection of putative cysteine proteinase activity). Bovine nasal cartilage aggrecan at a concentration of 10 mg/ml was incubated overnight at 37°C with 10 p1 of cell or tissue extract and buffer in a total volume of 50 j1. Assays were terminated by boiling for five minutes, and the assay mixture was deglycosylated before loading on to filters.
N-TERMINAL SEQUENCE ANALYSIS OF AGGRECAN CORE PROTEIN FRAGMENTS RELEASED INTO THE CULTURE MEDIUM
The cartilage from one nasal septum was prepared essentially as described previously.6
The tissue was then divided into two and each half was cultured for five days, with one change of medium, in the presence or absence of rhTNFa (3 nM PAGE in the presence of SDS, and western blotting, whereas endogenous aggrecan was excluded from entering the gel due to its large size. We found no evidence of cleavage of deglycosylated exogenous proteoglycan during a two day culture period in the presence of explants treated with 0.3 nM rhIL-la. There was no appearance of BC3 reactivity as determined by western blotting ( The IC50 was -50 nM (20 jig/ml), suggesting a specific molecular interaction of some kind. Aggrecan fragments (ng/dot) Figure 4 Semi-logarithmic standard curves for the quantitative detection ofBC3 reactive aggrecan fragments. The readings were obtained by densitometric scanning of dots that had been loaded with increasing amounts of aggrecan fragments obtainedfrom cartilage explant conditioned media (horizontal axis). The experiments differed in terms of the amounts of antibody that were used: * BC3 1:1000, second antibody 1:1000; * BC3 1:1000, second antibody 1:500; * BC3 1:1000, second antibody 1:250; V BC3 1:500, second antibody 1:1000; 0 BC3 1:500, second antibody 1:500; BC3 1:500, second antibody 1:250.
DOT BLOT IMMUNOASSAYS FOR AGGRECANASE CLEAVED AGGRECAN
We used aggrecanase generated aggrecan fragments to develop a dot blot assay using BC3. The assay specifically detected aggrecanase cleaved fragments of aggrecan but did not detect uncleaved aggrecan from bovine nasal cartilage (fig 3) . The lack of BC3 reactivity in our preparation of aggrecan extracted from bovine cartilage was an important prerequisite for the aggrecanase assay in which uncleaved exogenous aggrecan acts as the substrate. Densitometry of the signals produced from the dot blots (fig 4) indicated that there was a dose response up to at least 100 ng of sGAG (estimated by the dye-binding assay22 before deglycosylation), equivalent to 0.25 pmol aggrecan, with 1 ng being the limit of detection. The relation between the amount of aggrecan fragments added to a dot and the subsequent density was not linear, but when the log of the dose was plotted against the density (fig 4) an approximate straight line was produced. The sensitivity of the assay (but not the useful range) depended on the concentrations of BC3 and the second antibody.
AGGRECANASE ASSAYS ON CHONDROCYTE LYSATES AND CULTURE MEDIA
Crushed cartilage extracts, lysed chondrocytes, and conditioned media from chondrocyte cultures were assayed for aggrecanase activity. Using both western or dot blots, BC3 reactivity could not be detected following incubation of intact aggrecan with extracts, lysates, or conditioned medium under two sets of conditions chosen for the manifestation of serine, cysteine and metalloproteinase activities. Increasing the concentration of Triton X-100 in the lysis buffer from 0.1-3%, a concentration that is known to solubilise a membrane-bound metalloproteinase,"6 did not lead to detection of BC3 reactivity associated with the supernatants. Aggrecanase activity was not detected in vitro despite the presence of endogenous BC3 reactive fragments in the chondrocyte lysates and the conditioned medium ( fig 1B, fig 5) , which were removed by ion-exchange chromatography prior to assay ( fig 5) .
Discussion
The release from cartilage cultures of aggrecan fragments having the sequence ARGS at the N-terminus, and the presence of similar fragments in synovial fluid has been reported.6 [12] [13] [14] [15] [16] [17] [18] The existence of this N-terminus is consistent with a large proportion of hydrolysed aggrecan being produced by an unidentified glutamyl endopeptidase, termed aggrecanase. We have confirmed that a monoclonal antibody recognising the ARGS neoepitope specifically detects aggrecanase cleaved fragments of aggrecan in the culture media of cartilage explants treated with IL-I or Ret, and shown for the first time the presence of aggrecanase generated aggrecan fragments in cultures treated with TNF.
One of the aims of this study was to develop an in vitro assay for aggrecanase activity. We were able, specifically, to detect aggrecanase cleaved aggrecan using BC3 in a dot blot assay. The resistance of exogenous deglycosylated aggrecan to hydrolysis by aggrecanase, and the inhibitory activity of exogenous aggrecan, may suggest a role for sGAG chains in the regulation of aggrecan breakdown. We cannot, however, discount the possibility that our preparations of deglycosylated aggrecan contained a component other than aggrecan that was inhibiting endogenous proteoglycan breakdown, although we simply added back the components of our explant system that were present during the breakdown of endogenous proteoglycan. There has been a report of the inhibition of cartilage explant proteoglycan breakdown by exogenously added hyaluronate31; we did not take any steps to remove hyaluronate from our aggrecan preparation, and this molecule could, therefore, have contributed to the inhibition of proteoglycan breakdown in our experiments. However, the IC50 for the effect of exogenous hyaluronate was 500 jg/ml,3' whereas our preparation of deglycosylated aggrecan was much more potent, with an IC5, of-20 ,ug/ml.
The hydrolysis of aggrecan may be regulated by association with cell surface components. For instance, it is known that binding, internalisation, and breakdown of hyaluronate is mediated by its cell surface receptor, CD44, 32 and that the t,5 for turnover of both hyaluronate and aggrecan is similar.33 As previously noted,34this apparent co-ordinate regulation, and the likelihood that hyaluronate destined for breakdown will be associated with numerous aggrecan molecules, might suggest that the internalisation of hyaluronate and breakdown of aggrecan are functionally and topographically linked.The inhibition of aggrecan breakdown by exogenous hyaluronate lacking bound aggrecan" could then be explained by competition for CD44. It is known that chondrocytes express the haematopoietic variant of CD4435 and that the number of cell surface CD44 molecules is up-regulated by IL-1 treatment36 that also leads to increased aggrecan breakdown. Thus, a molecular association between CD44 and a cell surface proteinase, aggrecanase, may exist. The hypothesis would therefore predict that exogenous aggrecan was resistant to cleavage because it was not bound to CD44 via hyaluronate, rather than because it was deglycosylated.
